Skip to main content
. 2020 Nov 16;12(11):3389. doi: 10.3390/cancers12113389

Figure 1.

Figure 1

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) in human cancer. (A) Genetic landscape of PRKDC (encoding DNA-PKcs) across the pan-cancer cohort in The Cancer Genome Atlas (TCGA). Data were downloaded from the cBioPortal database (https://www.cbioportal.org/). PRKDC was queried in TCGA pan-cancer cohort. (B) Bar plots showing the PRKDC gene expression profile across all tumor samples and paired normal tissues. The height of the bar represents the median expression of the indicated tumor (in red) or normal (in blue) tissue. (C) Forest blots showing the survival analysis of cancer patients stratified by the gene expression of PRKDC across the TCGA pan-solid cancer cohort. Only significant (p < 0.05) results were presented. The “high” and “low” expression groups were stratified by the optimal cutoff value using “survminer” and “survival” packages in R software. N, the total number in each group. Scale line indicates the 95% confidence interval for effect estimate for each survival-influencing factor with the hazard ratio showing to the right. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma. * p < 0.05, ** p < 0.01, *** p < 0.001. The detailed information about the bioinformatic analysis can be found in the Supplementary Material.